Supplementary Table S2 from First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Table S2 shows LRRC15 IHC expression in tumor and stroma of patients with sarcoma treated ABBV-085 monotherapy at 3.6 or 4.2 mg/kg
Authors: George D. Demetri, Jason J. Luke, Antoine Hollebecque, John D. Powderly, Alexander I. Spira, Vivek Subbiah, Louie Naumovski, Chris Chen, Hua Fang, Dominic W. Lai, Huibin Yue, Akshanth R. Polepally, James W. Purcell, Randy Robinson, Padmanee Sharma, James P. Allison, Anthony Tolcher, Victor M. Villalobos
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362432328